David J Reeves

16PUBLICATIONS
4CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 07, 2026
Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

|Dec 01, 2025
Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Josie J Hockett, Molly E Keller, David J Reeves

|Jul 24, 2024
Reply: Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.

Madeline D Schultze, David J Reeves

|Jan 18, 2024
Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.

Madeline D Schultze, David J Reeves

|Jan 13, 2023
Impact of diabetes (type 2) and glycemic control on health-related outcomes of patients receiving chemotherapy for non-metastatic breast cancer: a retrospective analysis.

Allison L Phillips, David J Reeves, Susan Storey

|Oct 21, 2022
Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.

Allison L Phillips, David J Reeves

Pageof 3

Frequent Collaborators

1 joint publications

Lindsay M Saum

1 joint publications

Allison L Phillips

1 joint publications

Susan Storey

1 joint publications

Madeline D Schultze